Voie orale And NotP. Falardeau
List of bibliographic references
Number of relevant bibliographic references: 15.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000401 | P.-J. Blanchet [Canada] ; B. Lalonde [Canada] ; G.-J. Lavigne [Canada] | Douleur orofaciale et désordres oromoteurs |
| 000712 | Kaveh M. Koochesfahani [Canada] ; Raul De La Fuente-Fernandez [Canada, Espagne] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Lakshmi N. Yatham [Canada] ; Thomas J. Ruth [Canada] ; Stephan Blinder [Canada] ; A. Jon Stoessl [Canada] | Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients : Positron emission tomographic studies |
| 000716 | Reyniel Cruz-Aguado [Canada] ; Daniella Winkler ; Christopher A. Shaw | Lack of behavioral and neuropathological effects of dietary β-methylamino-L-alanine (BMAA) in mice |
| 000938 | Jackalina Van Kampen [Canada] ; Harold Robertson [Canada] ; Theo Hagg [Canada] ; Robert Drobitch [Canada] | Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease |
| 000A80 | Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
| 000B26 | Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
| 000B32 | Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
| 000C24 | Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
| 000C60 | V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
| 000D64 | S. Rohatagi [États-Unis] ; J. S. Barrett [États-Unis] ; K. E. Dewitt [États-Unis] ; D. Lessard [Canada] ; R. J. Morales [États-Unis] | Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system |
| 000E13 | P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
| 001048 | N. R. C. Campbell ; D. Rankine ; A. E. Goodridge ; B. B. Hasinoff ; M. Kara | Sinemet-ferrous sulphate interaction in patients with Parkinson's disease |
| 001084 | W. G. Vincken ; C. M. Darauay ; M. G. Cosio | Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease |
| 001131 | T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease |
| 001152 | MOHAMMAD SHENASA ; M. Fromer ; G. Faugere ; R. Nadeau ; R. A. Leblanc ; C. Lambert ; MOHAMMAD ALI SADR-AMELI | Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome |
| This area was generated with Dilib version V0.6.29. |  |